Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers

抗原 癌症研究 免疫学 医学
作者
Lena Fischer‐Riepe,Sareetha Kailayangiri,Katharina Zimmermann,Rita Pfeifer,Michael Aigner,Bianca Altvater,Sascha Kretschmann,Simon Völkl,Jordan Hartley,Celine Dreger,Katja Petry,Andreas Bosio,Angelika von Döllen,Wolfgang Hartmann,Holger N. Lode,Dennis Görlich,Andréas Mackensen,Melanie Jungblut,Axel Schambach,Hinrich Abken
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:30 (16): 3564-3577 被引量:45
标识
DOI:10.1158/1078-0432.ccr-23-3157
摘要

PURPOSE: Cytokine-engineering of chimeric antigen receptor-redirected T cells (CAR T cells) is a promising principle to overcome the limited activity of canonical CAR T cells against solid cancers. EXPERIMENTAL DESIGN: We developed an investigational medicinal product, GD2IL18CART, consisting of CAR T cells directed against ganglioside GD2 with CAR-inducible IL18 to enhance their activation response and cytolytic effector functions in the tumor microenvironment. To allow stratification of patients according to tumor GD2 expression, we established and validated immunofluorescence detection of GD2 on paraffin-embedded tumor tissues. RESULTS: Lentiviral all-in-one vector engineering of human T cells with the GD2-specific CAR with and without inducible IL18 resulted in cell products with comparable proportions of CAR-expressing central memory T cells. Production of IL18 strictly depends on GD2 antigen engagement. GD2IL18CART respond to interaction with GD2-positive tumor cells with higher IFNγ and TNFα cytokine release and more effective target cytolysis compared with CAR T cells without inducible IL18. GD2IL18CART further have superior in vivo antitumor activity, with eradication of GD2-positive tumor xenografts. Finally, we established GMP-compliant manufacturing of GD2IL18CART and found it to be feasible and efficient at clinical scale. CONCLUSIONS: These results pave the way for clinical investigation of GD2IL18CART in pediatric and adult patients with neuroblastoma and other GD2-positive cancers (EU CT 2022- 501725-21-00). See related commentary by Locatelli and Quintarelli, p. 3361.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
刚刚
1秒前
追寻天菱完成签到,获得积分10
1秒前
焦糖布丁发布了新的文献求助10
1秒前
1秒前
zhongchengcs完成签到,获得积分10
1秒前
Azhar发布了新的文献求助10
1秒前
2秒前
3秒前
3秒前
斯文败类的应助被ke采纳,获得10
4秒前
科研通AI6.2的应助被LemonChen采纳,获得10
4秒前
桐桐的应助被精明的烨霖采纳,获得10
4秒前
5秒前
顾乐乐发布了新的文献求助10
5秒前
见贤思齐发布了新的文献求助10
5秒前
见贤思齐发布了新的文献求助10
5秒前
见贤思齐发布了新的文献求助10
5秒前
见贤思齐发布了新的文献求助10
5秒前
见贤思齐发布了新的文献求助10
5秒前
见贤思齐发布了新的文献求助10
5秒前
见贤思齐发布了新的文献求助10
5秒前
嘻嘻哈哈的应助被晏清采纳,获得10
6秒前
llly完成签到,获得积分10
6秒前
充电宝的应助被Lucky采纳,获得10
6秒前
7秒前
Zzz发布了新的文献求助10
7秒前
联联完成签到 ,获得积分10
7秒前
Yeager完成签到,获得积分10
8秒前
8秒前
8秒前
likang发布了新的文献求助10
8秒前
8秒前
Jasper的应助被开心德地采纳,获得10
8秒前
9秒前
9秒前
汉堡包的应助被gtgyh采纳,获得30
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188956
求助须知:如何正确求助?哪些是违规求助? 9576517
关于积分的说明 21848214
捐赠科研通 7786997
什么是DOI,文献DOI怎么找? 3435467
关于科研通互助平台的介绍 2559698
邀请新用户注册赠送积分活动 2482391